减少荷兰宫颈癌筛查中hrHPV阳性女性不必要的阴道镜转诊:模型研究
结果显示,将转诊条件调整为「HPV16/18+且ASC-US+」和「HPV其他高危+且HSIL+」并将复查间隔延长至12个月,可减少40%的不必要转诊,且宫颈癌发病率增加0%、死亡率降低1%。在不大幅增加发病和死亡的前提下,应实施HPV16或HPV16/18基因分型并采用12个月复查间隔。
要点
- HPV16/18基因分型联合12个月复查可减少40%不必要转诊,发病率+0%、死亡率-1%。
- 不依赖基因分型时,将直接转诊条件调整为LSIL并12个月复查可减少37%不必要转诊,但发病率+2%。
- 24种分诊策略对不必要转诊的影响从-72%到+35%不等。
核心结论
- 在荷兰宫颈癌筛查项目中,为在不使发病率和死亡率增加超过2%的前提下减少不必要转诊,应实施HPV16或HPV16/18基因分型并采用12个月复查间隔。
主要发现
- 24种分诊策略对不必要转诊的影响范围为-72%至+35%。
- 将转诊条件调整为「HPV16/18+且ASC-US+」和「HPV其他高危+且HSIL+」并将复查间隔延长至12个月,不必要转诊减少40%,发病率+0%,死亡率-1%。
- 不依赖基因分型时,将直接转诊条件调整为LSIL并12个月复查,不必要转诊减少37%,发病率+2%,死亡率+0%。
关键数值与推荐
- 直接转诊条件涉及ASC-US、LSIL、HSIL,并以HPV基因型16/18/其他高危为条件。
- 分诊检测类型为单独细胞学或联合hrHPV检测。
- 分诊检测时间为6或12个月。
临床怎么用
- 在HPV为基础的宫颈癌筛查中,可考虑采用HPV16/18基因分型联合12个月复查策略以减少不必要的阴道镜转诊。
- 若不使用基因分型,可调整直接转诊条件为LSIL并12个月复查,但需注意发病率可能增加2%。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: With the implementation of primary high-risk human papillomavirus (hrHPV) screening in the Netherlands, an increase was observed in the number of unnecessary referrals (≤Cervical Intraepithelial Neoplasia (CIN) 1) to colposcopy. We aimed to investigate which alternative triage strategies safely reduce unnecessary referrals in HPV-based cervical cancer screening programmes. METHODS: Microsimulation model MISCAN was used to simulate an unvaccinated cohort of ten million 30-year old Dutch women. We calculated unnecessary referrals, cervical cancer incidence, mortality, costs and QALYs for 24 triage strategies. Condition for direct referral (atypical squamous cells of undetermined significance (ASC-US), low-grade squamous intraepithelial lesions (LSIL), high-grade squamous intraepithelial lesions (HSIL), conditional on HPV-genotype 16/18/other high risk (OHR)), type of triage test (cytology alone or combined with hrHPV) and time to triage test (6 or 12 months) was varied. RESULTS: The 24 triage strategies had varying effects on the number of unnecessary referrals ranging from -72% to +35%. Adjusting conditions for referral to 'HPV16/18+ and ASC-US+' and 'HPVOHR+ and HSIL+' and extending the interval between tests to 12 months resulted in a reduction in unnecessary referrals of 40% (incidence +0%, mortality -1%). Reduction in unnecessary referrals without genotyping was achieved by adjusting conditions for direct referral to LSIL (12 months to repeat test) (unnecessary referrals -37%, incidence +2%, mortality +0%). CONCLUSIONS: To reduce the number of unnecessary referrals without increasing incidence and mortality by more than 2% in the Dutch cervical cancer screening programme, genotyping for HPV16 or HPV16/18 should be implemented with 12 months to repeat testing.
引用
- Kaljouw S, Jansen EEL, Aitken CA, et al. Reducing unnecessary referrals for colposcopy in hrHPV-positive women within the Dutch cervical cancer screening programme: A modelling study. Gynecol Oncol. 2021. PMID: 33451725. doi:10.1016/j.ygyno.2020.12.038
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。